Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
November 2021
-
Key Release
Novartis verkauft ihre Roche-Beteiligung in einer bilateralen Transaktion an Roche
Ad-hoc-Mitteilung gemäss Art. 53 KR Novartis und Roche vereinbaren bilaterale Transaktion zum Verkauf von Roche-Inhaberaktien im Besitz von Novartis zu einem Gesamtpreis von USD 20,7 Mrd. Der… -
Story Access to Healthcare
To make a difference, start with patients
John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.
October 2021
-
Media Release
FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous… -
Featured News
Sound Up for Lung Cancer
It’s time to change the conversation. Patient inspired and community led, Sound Up aims to empower people affected by lung cancer in raising the volume to vocally self-advocate.
-
Media Release
Novartis receives priority review by US FDA and filing acceptance by EMA for Kymriah® to treat patients with relapsed or refractory follicular lymphoma
Filings supported by pivotal ELARA trial, where treatment with Kymriah showed robust response rates and remarkable safety profile in adult patients with relapsed or refractory (r/r) follicular… -
Key Release
Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz
Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +5% (cc¹, +6% USD) Innovative Medicines grew +7% (cc, +8% USD)Strong performance of key growth drivers: Entresto (+44% cc), Cosentyx… -
Key Release
Novartis erzielt im dritten Quartal solide Ergebnisse – mit starkem Wachstum bei Innovative Medicines. Das Unternehmen kündigt eine strategische Überprüfung von Sandoz an
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz stieg im dritten Quartal um +5% (kWk¹, +6% USD) Die Division Innovative Medicines wuchs um +7% (kWk, +8% USD)Starke Performance der… -
Key Release
Novartis réalise de solides résultats au 3e trimestre, avec une forte croissance d’Innovative Medicines, et annonce un examen stratégique de Sandoz
Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du T3 en progression de +5% (tcc¹, +6% USD)Innovative Medicines: hausse de +7% (tcc, +8% USD)Forte performance des moteurs de… -
Story Access to Healthcare
Demystifying the science of myelodysplastic syndromes
Novartis works with visual artist Noma Bar and international patient group MDS Alliance to send a message of hope to people living with myelodysplastic syndromes.
-
Key Release
Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer
Ad hoc announcement pursuant to Art. 53 LR CANOPY-1 Phase III study did not meet its primary endpoints of overall survival (OS) and progression-free survival (PFS)… -
Media Release
Novartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccine
At least 24 million doses of the mRNA-based vaccine will be filled in 2022 into vials under sterile conditions at Novartis Technical Operations state-of-the-art facility in Ljubljana, Slovenia New… -
Media Release
Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killer
Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (…